A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells
Name
Chen-2010-A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells.pdf
Size
2.32 MB
Format
Adobe PDF
Checksum (MD5)
af93635e52aa08d48dbf498ef137a2d5
Author(s) • • • • • • •
Chen, Xinyuan
Kim, Pilhan
Farinelli, Bill
Doukas, Apostolos
Yun, Seok-Hyun
Gelfand, Jeffrey A.
Anderson, R. Rox
Wu, Mei X.
Date Issued
October 2010
Journal
PLoS ONE
Publisher
Public Library of Science
Citation
Chen Xinyuan, et al. "A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells." 2010 PLoS ONE 5(10).
Version
Final published version
Abstract
Background
Development of a potent vaccine adjuvant without introduction of any side effects remains an unmet challenge in the field of the vaccine research.
Methodology/Principal Findings
We found that laser at a specific setting increased the motility of antigen presenting cells (APCs) and immune responses, with few local or systemic side effects. This laser vaccine adjuvant (LVA) effect was induced by brief illumination of a small area of the skin or muscle with a nondestructive, 532 nm green laser prior to intradermal (i.d.) or intramuscular (i.m.) administration of vaccines at the site of laser illumination. The pre-illumination accelerated the motility of APCs as shown by intravital confocal microscopy, leading to sufficient antigen (Ag)-uptake at the site of vaccine injection and transportation of the Ag-captured APCs to the draining lymph nodes. As a result, the number of Ag+ dendritic cells (DCs) in draining lymph nodes was significantly higher in both the 1° and 2° draining lymph nodes in the presence than in the absence of LVA. Laser-mediated increases in the motility and lymphatic transportation of APCs augmented significantly humoral immune responses directed against a model vaccine ovalbumin (OVA) or influenza vaccine i.d. injected in both primary and booster vaccinations as compared to the vaccine itself. Strikingly, when the laser was delivered by a hair-like diffusing optical fiber into muscle, laser illumination greatly boosted not only humoral but also cell-mediated immune responses provoked by i.m. immunization with OVA relative to OVA alone.
Conclusion/Significance
The results demonstrate the ability of this safe LVA to augment both humoral and cell-mediated immune responses. In comparison with all current vaccine adjuvants that are either chemical compounds or biological agents, LVA is novel in both its form and mechanism; it is risk-free and has distinct advantages over traditional vaccine adjuvants.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0013776